Investigation of Fugitive Aerosols Released into the Environment during High-Flow Therapy
Open Access
- 1 June 2019
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (6) , 254
Abstract
Background: Nebulised medical aerosols are designed to deliver drugs to the lungs to aid in the treatment of respiratory diseases. However, an unintended consequence is the potential for fugitive emissions during patient treatment, which may pose a risk factor in both clinical and homecare settings. Methods: The current study examined the potential for fugitive emissions, using albuterol sulphate as a tracer aerosol during high-flow therapy. A nasal cannula was connected to a head model or alternatively, a interface was connected to a tracheostomy tube in combination with a simulated adult and paediatric breathing profile. Two aerodynamic particle sizers (APS) recorded time-series aerosol concentrations and size distributions at two different distances relative to the simulated patient. Results: The results showed that the quantity and characteristics of the fugitive emissions were influenced by the interface type, patient type and supplemental gas-flow rate. There was a trend in the adult scenarios; as the flow rate increased, the fugitive emissions and the mass median aerodynamic diameter (MMAD) of the aerosol both decreased. The fugitive emissions were comparable when using the adult breathing profiles for the nasal cannula and tracheostomy interfaces; however, there was a noticeable distinction between the two interfaces when compared for the paediatric breathing profiles. The highest recorded aerosol concentration was 0.370 ± 0.046 mg m−3 from the tracheostomy interface during simulated paediatric breathing with a gas-flow rate of 20 L/min. The averaged MMAD across all combinations ranged from 1.248 to 1.793 µm by the APS at a distance of 0.8 m away from the patient interface. Conclusions: Overall, the results highlight the potential for secondary inhalation of fugitive emissions released during simulated aerosol treatment with concurrent high-flow therapy. The findings will help in developing policy and best practice for risk mitigation from fugitive emissions.Keywords
Funding Information
- Science Foundation Ireland (17/IFB/5399)
This publication has 40 references indexed in Scilit:
- Exposure of home-attending healthcare workers to aerosolized medications (simulation study)Journal of Aerosol Science, 2019
- In Vitro Study of the Effect of Breathing Pattern on Aerosol Delivery During High-Flow Nasal TherapyPulmonary Therapy, 2019
- In Vitro Determination of the Main Effects in the Design of High-Flow Nasal Therapy Systems with Respect to Aerosol PerformancePulmonary Therapy, 2018
- Fill volume, humidification and heat effects on aerosol delivery and fugitive emissions during noninvasive ventilationJournal of Drug Delivery Science and Technology, 2017
- PM exposure variations due to different time activity profile simulations within a single dwellingBuilding and Environment, 2017
- Characterization of indoor aerosol temporal variations for the real-time management of indoor air qualityAtmospheric Environment, 2015
- A simulation study of the changes in PM2.5 concentrations due to interzonal airflow variations caused by internal door opening patternsAtmospheric Environment, 2014
- The Use of Condensational Growth Methods for Efficient Drug Delivery to the Lungs during Noninvasive Ventilation High Flow TherapyPharmaceutical Research, 2013
- In vitro comparison of heliox and oxygen in aerosol delivery using pediatric high flow nasal cannulaPediatric Pulmonology, 2011
- Particle deposition rates in residential housesAtmospheric Environment, 2005